- cafead Apr 08, 2024 at 11:34: AM
via The third time is decidedly not the charm for Supernus and its Parkinson’s disease infusion pump.
After two prior attempts to win FDA approval for its apomorphine infusion device for the continuous treatment of motor fluctuations (or “off” episodes) in Parkinson’s disease patients, the agency has once again rejected the therapy.
article source
After two prior attempts to win FDA approval for its apomorphine infusion device for the continuous treatment of motor fluctuations (or “off” episodes) in Parkinson’s disease patients, the agency has once again rejected the therapy.
article source